CARING: Chronotherapy With Low-dose Aspirin for Primary Prevention

Sponsor

University of Vigo (Other)

Overall Status

Recruiting

CT.gov ID

NCT00725127

Collaborator

(none)

3,200

Enrollment

Locations

Arms

212

Duration (Months)

168.4

Patients Per Site

0.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Brief summary:

Aspirin (ASA) has been shown to provide marked benefits in primary and secondary prevention of cardiovascular events. Substantial evidence suggests that low-dose ASA therapy should also be used as a primary prevention strategy in men and women with diabetes who are at high cardiovascular risk. On the other hand, there is current evidence on the potential benefits of low-dose ASA therapy in subjects with impaired fasting glucose, including those with metabolic syndrome. Most important, previous laboratory animal and clinical trial research convincingly demonstrates administration time-dependent (with reference to circadian rhythms) effects of ASA. Thus, the effects of ASA upon lipoperoxides, b-adrenergic receptors, and blood pressure (BP) in clinically healthy subjects depend on the circadian timing of ASA administration. The administration-time-dependent influence of ASA on BP was previously demonstrated in a randomized trial on healthy women and other independent double-blind, randomized, placebo-controlled clinical trials conducted, first, on clinically healthy subjects, a second one on normotensive and hypertensive subjects, a third one on pregnant women at high risk for preeclampsia and a fourth one in previously untreated patients with mild hypertension. The findings of these BP studies are consistent; BP-lowering effect of low-dose ASA is achieved when administered at bedtime but not upon awakening.

In keeping with the chronopharmacological effects of ASA and the previous findings suggesting that ASA at low dose may exert a potential beneficial effect on BP, endothelium function and cardiovascular function, this prospective, randomized, parallel-arm study will investigate the potential influence of ASA on the primary prevention of cardiovascular, cerebrovascular and renal events in subjects with either impaired fasting glucose (≥ 100 mg/dl) or previous diagnosis of type 2 diabetes mellitus, who will receive low-dose ASA (100 mg/day) at different circadian times (upon awakening or at bedtime) in relation to their rest-activity cycle.

Condition or Disease	Intervention/Treatment	Phase
Type 2 Diabetes	Drug: aspirin Drug: aspirin	Phase 4

Study Design

Study Type:

Interventional

Anticipated Enrollment :

3200 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

Chronotherapy With Low-dose Aspirin for Primary Prevention of Cardiovascular Events in Subjects With Impaired Fasting Glucose or Diabetes (CARING Study).

Study Start Date :

Oct 1, 2008

Anticipated Primary Completion Date :

Dec 1, 2025

Anticipated Study Completion Date :

Jun 1, 2026

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: 1 100 mg/day ASA upon awakening.	Drug: aspirin 100 mg/day upon awakening for five years Other Names: Aspirin on awakening
Active Comparator: 2 100 mg/day ASA at bedtime	Drug: aspirin 100 mg/day at bedtime for five years Other Names: Aspirin at bedtime

Arm

Intervention/Treatment

Active Comparator: 1

100 mg/day ASA upon awakening.

Drug: aspirin

100 mg/day upon awakening for five years

Other Names:

Aspirin on awakening

Active Comparator: 2

100 mg/day ASA at bedtime

Drug: aspirin

100 mg/day at bedtime for five years

Other Names:

Aspirin at bedtime

Outcome Measures

Primary Outcome Measures

To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration in subjects with impaired fasting glucose or type 2 diabetes on primary prevention of cardiovascular, cerebrovascular and renal fatal, and non-fatal events. [Five years]

Secondary Outcome Measures

To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration on primary prevention of cardiovascular fatal and non-fatal events (including cardiovascular death, myocardial infarction, angina pectoris, and coronary revascularization). [Five years]
To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration on primary prevention of cerebrovascular fatal and non-fatal events (including hemorrhagic stroke, ischemic stroke, and transient ischemic attack). [Five years]
To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration on primary prevention of chronic kidney disease and/or congestive heart failure, and/or peripheral artery disease. [Five years]
To demonstrate that 100 mg/day ASA at bedtime offers a similar safety profile than 100 mg/day ASA upon awakening [Five years]
To demonstrate that compliance with 100 mg/day ASA at bedtime is similar to that with 100 mg/day ASA upon awakening. [Five years]
To evaluate, for all previous objectives, potential gender differences in the benefits of low-dose ASA for primary prevention. [Five years]
To evaluate, for all previous objectives, potential differences in the benefits of low-dose ASA for primary prevention between patients with and without diabetes. [Five years]
To evaluate, for all previous objectives, potential differences in the benefits of low-dose ASA for primary prevention between subjects with and without metabolic syndrome. [Five years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

50 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Male or female subjects ≥ 50 years of age.
Impaired fasting glucose (≥ 100 and < 126 mg/dl) in the last available blood test prior (≤ 3 months) to randomization, or diagnosis of type 2 diabetes prior to randomization.
All subjects must have at randomization a conventional clinic systolic/diastolic BP < 160/100 mmHg.
Informed consent to participate in the study prior to any study procedures.

Exclusion Criteria:

Known or suspected contraindications, including history of allergy to ASA.
Uncontrolled essential hypertension of Grade 2-3, i.e., systolic BP ≥ 160 mmHg and/or diastolic BP ≥ 100 mmHg before randomization.
Evidence of a secondary form of hypertension, to include coarctation of the aorta, hyperaldosteronism, renal artery stenosis, or pheochromocytoma.
Known Keith-Wagener grade III or IV hypertensive retinopathy.
History of hypertensive encephalopathy, cerebrovascular event, transient ischemic cerebral attack, or myocardial infarction prior to randomization.
Type 1 diabetes mellitus.
History of heart failure.
Second or third degree heart block without a pacemaker.
Concomitant unstable angina pectoris.
Concomitant potentially life threatening arrhythmia or symptomatic arrhythmia.
Clinically significant valvular heart disease.
Evidence of hepatic disease as determined by one of the following: ALT or AST values > 2 x UNL known before randomization, a history of hepatic encephalopathy, history of esophageal varices, or history of portocaval shunt.
Diagnosis of chronic kidney disease prior to randomization.
History of malignancy including leukemia and lymphoma (but not basal cell skin cancer), or any other severe, life-threatening disease within the past five years.
Any previous history of a systemic autoimmune disease.
History of drug or alcohol abuse within the last two years.
Use of any disallowed concomitant medication.
Inability to communicate and comply with all study requirements.
Persons directly involved in the execution of this protocol.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	CS Friol	Friol	Lugo	Spain	27220
2	CS Baiona	Baiona	Pontevedra	Spain	36300
3	CS Bueu	Bueu	Pontevedra	Spain	36930
4	CS A Estrada	La Estrada	Pontevedra	Spain	26680
5	CS A Guarda	La Guardia	Pontevedra	Spain	36780
6	CS Valmiñor	Nigran	Pontevedra	Spain	36250
7	CS Panxón	Nigrán	Pontevedra	Spain	36340
8	CS Tomiño	Tomiño	Pontevedra	Spain	36200
9	Bioengineering & Chronobilogy Labs., University of Vigo	Vigo	Pontevedra	Spain	36200
10	CS Calle Cuba	Vigo	Pontevedra	Spain	36202
11	CS A Doblada	Vigo	Pontevedra	Spain	36205
12	CS Coia	Vigo	Pontevedra	Spain	36209
13	CS Sardoma	Vigo	Pontevedra	Spain	36214
14	CS Teis	Vigo	Pontevedra	Spain	36216
15	CS Vilaboa	Vilaboa	Pontevedra	Spain	36141
16	CS San Roque	Vilagarcía De Arousa	Pontevedra	Spain	36600
17	CS Fingoi	Lugo		Spain	27002
18	Complexo Hospitalario Universitario de Ourense	Orense		Spain	32005
19	CS Lerez	Pontevedra		Spain	36156